drugset / Trial / NCT01249690
Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
Phase 4
Unknown
100 enrolled
Second Military Medical University
Air Force Military Medical University, China · collabBeijing Jishuitan Hospital · collabFirst Affiliated Hospital, Sun Yat-Sen University · collabHarbin Hematology and Oncology Institute · collabInstitute of Hematology & Blood Diseases Hospital, China · collabPeking University People's Hospital · collabUnion hospital of Fujian Medical University · collabXiangya Hospital of Central South University · collabZhejiang University · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this study is to evaluate the efficacy of PAD-regimen and TAD-regimen in newly diagnosed multiple myeloma(MM).
Timeline
- Start
- 2010-06
- Primary completion
- 2012-06
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | — |
| Subject | Thalidomide | Other / unclassified | 200 mg | — |
| Background | Dexamethasone | Small molecule | 20 mg | — |
| Background | Pirarubicin | Small molecule | 10 mg | — |